nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Association Between Gender-Affirming Surgery and Improved Mental Health
May 10, 2021   

Gender-affirming surgery refers to any surgical procedures offered to affirm the gender identities of transgender and gender diverse people. Evidence supporting a positive effect of gender-affirming surgeries on mental health is largely derived from low-quality studies. A secondary analysis of the...
 Continue reading (Members only)
Psilocybin As Effective As Escitalopram At Reducing Depression
May 7, 2021   

Several studies have reported that psilocybin has antidepressant properties, however direct comparisons between established depression treatments and psilocybin are lacking. In a phase 2, double-blind randomized controlled trial included patients with long-term, moderate-to-severe major depressive disorder, over a six-week period. Patients were randomly...
 Continue reading (Members only)
Short Sleep Tied to Increased Dementia Risk
May 4, 2021   

In a recent study, the association between sleep dysregulation and dementia was examined. Data from 7,959 participants of the Whitehall II study was analyzed for sleep duration and the incidence of dementia, using a 25-year follow-up. A total of...
 Continue reading (Members only)
FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose
April 30, 2021   

The US Food and Drug Administration has approved Kloxxado (naloxone hydrochloride) nasal spray 8mg for its emergency treatment of known or suspected opioid overdose...
 Continue reading (Members only)
Mood Disorder Patients Experience Seasonal Changes In Varying Degrees
April 22, 2021   

Seasonal affective disorder is defined as depression that occurs with seasonality -typically occurring in the autumn and winter months and remitting in spring and summer. It is thought to be pathophysiologically related to circadian misalignment and can often be effectively treated, or even prevented, with light therapy and/or bupropion. Given that...
 Continue reading
Symptoms of Anxiety or Depressive Disorder Among Adults During the COVID-19 Pandemic
April 15, 2021   

Rapid monitoring of mental health status and access to care during the COVID-19 pandemic can help accelerate the deployment and evaluation of mental health services. To this end, the Center for Disease Control (CDC) partnered with the...
 Continue reading (Members only)
Guidelines For The Use Of Ketamine For Treatment-Resistant Depression
April 12, 2021   

An international expert opinion on the use of ketamine for treatment-resistant depression was recently published. Although the various formulations of ketamine have not been compared directly in randomized controlled trials, intranasal esketamine and intravenous ketamine have the strongest evidence of short-term efficacy and safety in patients with ..
 Continue reading
Disturbed Sleep and Depression in Children and Youths
April 9, 2021   

In a recently published meta-analysis, the relationship between disturbed sleep and depression was examined. A total of 22 studies were included in the study, of which 16 were included in the meta-analysis. Disturbed sleep was...
 Continue reading (Members only)
High-Risk Youth Population Are Not Receiving Behavioral Health Services
April 6, 2021   

Literature on pediatric mental health has suggested that adverse children’s experiences have been widespread and have gone unaddressed or untreated. A recent cross-sectional study was conducted to estimate the proportion of children with high levels of adverse children’s experiences or mental health symptoms who have not been receiving services from behavioral health professionals...
 Continue reading (Members only)
FDA Approves New Treatment For ADHD In Pediatric Patients
April 2, 2021   

A U.S. Food and Drug Administration approves viloxazine extended-release capsules for the treatment of attention-deficit hyperactivity disorder in pediatric patients 6 to 17 years of age...
 Continue reading
12345678910...
Top of Page